Matthew Baggott to N-Methyl-3,4-methylenedioxyamphetamine
This is a "connection" page, showing publications Matthew Baggott has written about N-Methyl-3,4-methylenedioxyamphetamine.
Connection Strength
2.360
-
Effects of 3,4-methylenedioxymethamphetamine on socioemotional feelings, authenticity, and autobiographical disclosure in healthy volunteers in a controlled setting. J Psychopharmacol. 2016 Apr; 30(4):378-87.
Score: 0.507
-
Intimate insight: MDMA changes how people talk about significant others. J Psychopharmacol. 2015 Jun; 29(6):669-77.
Score: 0.479
-
Preventing problems in Ecstasy users: reduce use to reduce harm. J Psychoactive Drugs. 2002 Apr-Jun; 34(2):145-62.
Score: 0.194
-
Caveat emptor: editors beware. Neuropsychopharmacology. 2001 Apr; 24(4):461-3.
Score: 0.181
-
Chemical analysis of ecstasy pills. JAMA. 2000 Nov 01; 284(17):2190.
Score: 0.176
-
Detection of acute 3,4-methylenedioxymethamphetamine (MDMA) effects across protocols using automated natural language processing. Neuropsychopharmacology. 2020 04; 45(5):823-832.
Score: 0.166
-
More about parkinsonism after taking ecstasy. N Engl J Med. 1999 Oct 28; 341(18):1400-1.
Score: 0.164
-
Effects of the Psychedelic Amphetamine MDA (3,4-Methylenedioxyamphetamine) in Healthy Volunteers. J Psychoactive Drugs. 2019 Apr-Jun; 51(2):108-117.
Score: 0.158
-
The effects of MDMA on socio-emotional processing: Does MDMA differ from other stimulants? J Psychopharmacol. 2016 12; 30(12):1248-1258.
Score: 0.131
-
MDMA effects consistent across laboratories. Psychopharmacology (Berl). 2014 Oct; 231(19):3899-905.
Score: 0.111
-
Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl). 2002 Aug; 162(4):396-405.
Score: 0.049
-
Cardiovascular effects of 3,4-methylenedioxymethamphetamine. A double-blind, placebo-controlled trial. Ann Intern Med. 2000 Dec 19; 133(12):969-73.
Score: 0.044